REG - Hikma Pharmaceutical - S&P upgrades Hikma to ‘BBB’

Hikma PharmaceuticalsAnnouncement

08/05/2025 11:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250508:nRSH8970Ha&default-theme=true

RNS Number : 8970H  Hikma Pharmaceuticals Plc  08 May 2025

S&P upgrades Hikma Pharmaceuticals PLC and its Senior Notes to 'BBB' on
continued good business momentum; outlook stable

 

London, 8 May 2025 - S&P has today announced that it has raised its
long-term issuer credit rating on Hikma Pharmaceuticals PLC (Hikma, Company)
and its $500 million notes outstanding due July 9, 2025, issued out of Hikma
Finance USA LLC, to 'BBB' from 'BBB-' with a stable outlook.  S&P said
its rating action reflects Hikma's good business momentum and ability to
maintain healthy growth prospects and stable credit metrics.

 

Khalid Nabilsi, CFO of Hikma said: "I am pleased that S&P have upgraded
Hikma today, strengthening our investment grade rating and confirming our
solid market position as well as our track record of profitability and cash
generation."

 

--  ENDS  --

Enquiries:

Hikma
(Investors)

 Susan Ringdal                                                                +44 (0)20 7399 2760/ +44 (0)7776 477050

 EVP, Strategic Planning and Global Affairs
 Guy Featherstone                                                             +44 (0)20 3892 4389/ +44 (0)7795 896738

 Director, Investor Relations
 Layan Kalisse                                                                +44 (0)20 7399 2788/ +44 (0)7970 709912

 Senior Associate, Investor Relations

 FTI Consulting (Media)

 Ciara Martin

                                                                              +44 (0)7779 775979

 

 

 

 

About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY)
(LEI:549300BNS685UXH4JI75) (rated BBB/stable S&P and BBB-/positive Fitch)

 

Hikma helps put better health within reach every day for millions of people
around the world. For more than 45 years, we've been creating high-quality
medicines and making them accessible to the people who need them.
Headquartered in the UK, we are a global company with a local presence across
North America, the Middle East and North Africa (MENA) and Europe, and we use
our unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed to our
customers, and the people they care for, and by thinking creatively and acting
practically, we provide them with a broad range of branded and non-branded
generic medicines. Together, our 9,500 colleagues are helping to shape a
healthier world that enriches all our communities. We are a leading licensing
partner, and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more information, please
visit: www.hikma.com (http://www.hikma.com)

©2025 Hikma Pharmaceuticals PLC. All rights reserved.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUPUACAUPAUBR